National Institute for Health and Clinical Excellence's (NICE) has recommended that Avastin (bevacizumab) should not to be considered as treatment for women diagnosed with breast cancer.

NICE said, "Making Avastin available on the NHS was not a good use of resources because of its high cost, and it lacked evidence to show patients would have a better quality of life".

The advisory body is neither satisfied with the efficiency of the drug nor with its price. The data provided in support of the drug is not impressive enough to prove that the combination of Avastin given with another Roche drug, Xeloda, in patients with advanced disease, can increase the longevity and quality of their life, in comparison to chemotherapy alone.

It has been explained that the drug works targeting the cancer tumor. It was being proposed that the drug would be considered as a part of the treatment along with capecitabine, a type of chemotherapy. The chemotherapy is especially for those patients, whose cancer has spread to other organs and parts of the body.

NICE Chief Sir Andrew Dillon asserted that they will not be recommending nay treatment, which fails to show better results than the current treatment.

While, a few of the breast cancer survivors suggest that if the drug won't have been recommended, they won't have overcome the disease.